Key facts
- This page summarizes Michael Secora's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 6 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 10 Oct 2024, 18:40.
Michael Secora - 08 Oct 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- RXRX
- Reported as of
- 08 Oct 2024
- Net transaction value
- -$15,306
- SEC form
- 4
- Accepted by SEC
- 10 Oct 2024, 18:40:44 UTC
- Prior SEC filing
- 12 Sep 2024
- Next SEC filing
- 14 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Jonathan Golightly, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Secora filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 10 Oct 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: -$15,306.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $87,412
- Shares
- +39,375
- Change %
- +2.8%
- Price
- $2.22
- Shares after
- 1,441,506
- Date
- 08 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
RXRX
transaction
Class A Common Stock
Sale
- Transaction value
- $94,756
- Shares
- -15,000
- Change %
- -1%
- Price
- $6.32
- Shares after
- 1,426,506
- Date
- 08 Oct 2024
- Ownership
- Direct
- Footnotes
- F1, F2
RXRX
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $87,412
- Shares
- +39,375
- Change %
- +2.8%
- Price
- $2.22
- Shares after
- 1,465,881
- Date
- 09 Oct 2024
- Ownership
- Direct
- Footnotes
- F1
RXRX
transaction
Class A Common Stock
Sale
- Transaction value
- $95,374
- Shares
- -15,000
- Change %
- -1%
- Price
- $6.36
- Shares after
- 1,450,881
- Date
- 09 Oct 2024
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RXRX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -39,375
- Change %
- -8%
- Price
- $0.000000
- Shares after
- 455,760
- Date
- 08 Oct 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 39,375
- Exercise price
- $2.22
- Footnotes
- F1, F4
RXRX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -39,375
- Change %
- -8.6%
- Price
- $0.000000
- Shares after
- 416,385
- Date
- 09 Oct 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 39,375
- Exercise price
- $2.22
- Footnotes
- F1, F4
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 685,177
- Date
- 08 Oct 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $2.22
- Footnotes
- F5
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,914
- Date
- 08 Oct 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 116,684
- Date
- 08 Oct 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $11.40
- Footnotes
- F6
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 404,857
- Date
- 08 Oct 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $8.55
- Footnotes
- F7
RXRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 348,380
- Date
- 08 Oct 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 0
- Exercise price
- $10.09
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $6.17 to $6.48 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $6.095 to $6.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Footnote F4
The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
Footnote F5
The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
Footnote F6
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F7
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Footnote F8
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.